Brain-Computer Interface Based Neuromodulation on Treatment of Depression
DOI:
https://doi.org/10.54097/sfx0ya89Keywords:
Depression treatment; Neuromodulation; Brain-computer interface.Abstract
Major Depressive Disorder (MDD) represents a significant societal burden, with traditional first-line treatments often falling short. This pressing issue has spurred the exploration of neuromodulation therapies, demonstrating superior efficacy compared to conventional pharmaceutical interventions. The present review provides a rigorous evaluation of four advanced neuromodulation techniques: Focal Electrically Administered Seizure Therapy (FEAST), Transcranial Magnetic Stimulation (TMS), Intermittent Theta-Burst Stimulation (iTBS), and Magnetic Seizure Therapy (MST). A comprehensive analytical comparison is offered, focusing on their efficacy, feasibility, economic considerations, and underlying mechanisms. Among these therapies, iTBS, integrated with Brain-Computer Interface (BCI) systems, has emerged as notably effective, with clinical trials indicating an average 80% efficacy at a reduced economic cost. FEAST and MST, supported by recent research, also exhibit strong efficacy, around 60%, although with more pronounced side effects. TMS, in contrast, exhibits a slightly reduced efficacy but is promising due to its minimal side effects. The review further delves into the transformative role of increasingly sophisticated BCI technologies in addressing previously identified challenges of neuromodulation therapy, such as adverse side effects, time-consuming procedures, and high costs. These technological advancements are elucidated, emphasizing their contribution to more precise therapy delivery and an enhanced patient experience. The review culminates in illuminating a pathway for the harmonious integration of neuromodulation therapies with traditional psychopharmacological treatments, positioning this integrative approach as a groundbreaking paradigm poised to redefine the landscape of depression treatment.
Downloads
References
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th edition), 2013.
https://www.nimh.nih.gov/health/statistics/major-depression
https://www.cdc.gov/suicide/suicide-data-statistics.html
https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report
Park LT, Carlos A Zarate Jr. Depression in the primary care setting. New England Journal of Medicine, 2019, 380: 2278–80.
https://www.ncbi.nlm.nih.gov/books/NBK559078/
Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis. JAMA, 2010, 303(1): 47–53.
Murphy SE, Capitão LP, Giles SL, Cowen PJ, Stringaris A, Harmer CJ. The knowns and unknowns of SSRI treatment in young people with depression and anxiety: Efficacy, predictors, and mechanisms of action. The Lancet Psychiatry. 2021, 8(9): 824–835.
Al-harbi KS. Treatment-resistant depression: Therapeutic trends, challenges, and Future Directions. Patient Preference and Adherence. 2012: 369.
Li M, Yao X, Sun L, Zhao L, Xu W, Zhao H, Zhao F, Zou X, Cheng Z, Li B, et al. Effects of electroconvulsive therapy on depression and its potential mechanism. Frontiers in Psychology. 2020, 11.
Cook, I. A., Espinoza, R., & Leuchter, A. F. Neuromodulation for depression: invasive and noninvasive (deep brain stimulation, transcranial magnetic stimulation, trigeminal nerve stimulation). Neurosurgery clinics of North America, 2014, 25(1): 103–116.
Spellman T, Peterchev AV, Lisanby SH. Focal electrically administered seizure therapy: A novel form of ect illustrates the roles of current directionality, polarity, and electrode configuration in seizure induction. Neuropsychopharmacology, 2009, 34(8): 2002–2010.
Sahlem GL, McCall WV, Short EB, Rosenquist PB, Fox JB, Youssef NA, Manett AJ, Kerns SE, Dancy MM, McCloud L, et al. A two-site, open-label, non-randomized trial comparing focal electrically-administered seizure therapy (feast) and right unilateral ultrabrief pulse electroconvulsive therapy (RUL-UBP ECT). Brain Stimulation, 2020, 13(5): 1416–1425.
Woletz M, Tik M, Pratapa N, Prinčič M, Schuler A, Windischberger C. Real-time neuronavigation feedback in concurrent TMS-fmri. Brain Stimulation, 2019, 12(2): 574–575.
Spellman T, Peterchev AV, Lisanby SH. Focal electrically administered seizure therapy: A novel form of ect illustrates the roles of current directionality, polarity, and electrode configuration in seizure induction. Neuropsychopharmacology, 2009, 34(8): 2002–2010.
Deng Z-D, Robins PL, Regenold W, Rohde P, Dannhauer M, Lisanby SH. How electroconvulsive therapy works in the treatment of depression: Is it the seizure, the electricity, or both? Neuropsychopharmacology, 2023.
Chahine G, Short B, Spicer K, Schmidt M, Burns C, Atoui M, George MS, Sackeim HA, Nahas Z. Regional cerebral blood flow changes associated with focal electrically administered seizure therapy (feast). Brain Stimulation, 2014, 7(3): 483–485.
Sahlem GL, McCall WV, Short EB, Rosenquist PB, Fox JB, Youssef NA, Manett AJ, Kerns SE, Dancy MM, McCloud L, et al. A two-site, open-label, non-randomized trial comparing focal electrically-administered seizure therapy (feast) and right unilateral ultrabrief pulse electroconvulsive therapy (RUL-UBP ECT). Brain Stimulation, 2020, 13(5): 1416–1425.
Nahas Z, Short B, Burns C, Archer M, Schmidt M, Prudic J, Nobler MS, Devanand DP, Fitzsimons L, Lisanby SH, et al. A feasibility study of a new method for electrically producing seizures in man: Focal electrically administered seizure therapy [feast]. Brain Stimulation, 2013, 6(3): 403–408.
Conroy SK, Holtzheimer PE. Neuromodulation strategies for the treatment of depression. American Journal of Psychiatry, 2021, 178(12): 1082–1088.
Cao K-X, Ma M-L, Wang C-Z, Iqbal J, Si J-J, Xue Y-X, Yang J-L. TMS-EEG: An emerging tool to study the neurophysiologic biomarkers of psychiatric disorders. Neuropharmacology, 2021, 197:108574.
Gogulski, J., Ross, J. M., Talbot, A., Cline, C. C., Donati, F. L., Munot, S., Kim, N., Gibbs, C., Bastin, N., Yang, J., Minasi, C., Sarkar, M., Truong, J., & Keller, C. J. Personalized Repetitive Transcranial Magnetic Stimulation for Depression. Biological psychiatry. Cognitive neuroscience and neuroimaging, 2023, 8(4): 351–360.
Arns M, Drinkenburg WH, Fitzgerald PB, Kenemans JL. Neurophysiological predictors of non-response to rtms in depression. Brain Stimulation, 2012, 5(4): 569–576.
Downar J, Daskalakis ZJ. New targets for RTMS in depression: A review of convergent evidence. Brain Stimulation, 2013, 6(3): 231–240.
Zanardini, R., Gazzoli, A., Ventriglia, M., Perez, J., Bignotti, S., Rossini, P. M., Gennarelli, M., & Bocchio-Chiavetto, L. Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. Journal of affective disorders, 2006, 91(1): 83–86.
Klomjai W, Katz R, Lackmy-Vallée A. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rtms). Annals of Physical and Rehabilitation Medicine, 2015, 58(4):208–213.
Hare BD, Duman RS. Prefrontal cortex circuits in depression and anxiety: Contribution of discrete neuronal populations and target regions. Molecular Psychiatry, 2020, 25(11): 2742–2758.
Ganho-Ávila A, Poleszczyk A, Mohamed MMA, Osório A. Efficacy of RTMS in decreasing postnatal depression symptoms: A systematic review. Psychiatry Research, 2019, 279: 315–322.
Hett D, Rogers J, Humpston C, Marwaha S. Repetitive transcranial magnetic stimulation (rtms) for the treatment of depression in adolescence: A systematic review. Journal of Affective Disorders, 2021, 278: 460–469.
Berlim MT, Van den Eynde F, Jeff Daskalakis Z. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rtms) for treating primary major depression: A meta-analysis of randomized, double-blind and sham-controlled trials. Neuropsychopharmacology, 2012, 38(4): 543–551.
Sonmez AI, Camsari DD, Nandakumar AL, Voort JL, Kung S, Lewis CP, Croarkin PE. Accelerated TMS for depression: A systematic review and meta-analysis. Psychiatry Research, 2019, 273: 770–781.
Singh, R., Sharma, R., Prakash, J., & Chatterjee, K. Magnetic seizure therapy. Industrial psychiatry journal, 2021, 30(Suppl 1): S320–S321.
Kosel M, Frick C, Lisanby SH, Fisch H-U, Schlaepfer TE. Magnetic seizure therapy improves mood in refractory major depression. Neuropsychopharmacology, 2003, 28(11): 2045–2048.
Kayser S, Bewernick BH, Grubert C, Hadrysiewicz BL, Axmacher N, Schlaepfer TE. Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression. Journal of Psychiatric Research, 2011, 45(5): 569–576.
Lisanby, S. H., Luber, B., Schlaepfer, T. E., & Sackeim, H. A. Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2003, 28(10): 1852–1865.
Tavares DF, Suen P, Rodrigues dos Santos CG, Moreno DH, Lane Valiengo LD, Klein I, Borrione L, Marques Forte P, Brunoni AR, Alberto Moreno R. Treatment of mixed depression with theta-burst stimulation (TBS): Results from a double-blind, randomized, Sham-controlled clinical trial. Neuropsychopharmacology, 2021, 46(13): 2257–2265.
Lee, C. W., Wu, H. F., Chu, M. C., Chung, Y. J., Mao, W. C., Li, C. T., & Lin, H. C. Mechanism of Intermittent Theta-Burst Stimulation in Synaptic Pathology in the Prefrontal Cortex in an Antidepressant-Resistant Depression Rat Model. Cerebral cortex (New York, N.Y. : 1991), 2021, 31(1): 575–590.
Voigt, J. D., Leuchter, A. F., & Carpenter, L. L. Theta burst stimulation for the acute treatment of major depressive disorder: A systematic review and meta-analysis. Translational psychiatry, 2021, 11(1): 330.
Cole, E. J., Stimpson, K. H., Bentzley, B. S., Gulser, M., Cherian, K., Tischler, C., Nejad, R., Pankow, H., Choi, E., Aaron, H., Espil, F. M., Pannu, J., Xiao, X., Duvio, D., Solvason, H. B., Hawkins, J., Guerra, A., Jo, B., Raj, K. S., Phillips, A. L., … Williams, N. R. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. The American journal of psychiatry, 2020, 177(8): 716–726.
Cole, E. J., Phillips, A. L., Bentzley, B. S., Stimpson, K. H., Nejad, R., Barmak, F., Veerapal, C., Khan, N., Cherian, K., Felber, E., Brown, R., Choi, E., King, S., Pankow, H., Bishop, J. H., Azeez, A., Coetzee, J., Rapier, R., Odenwald, N., Carreon, D., … Williams, N. R. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. The American journal of psychiatry, 2022, 179(2): 132–141.
Riedel, M., Möller, H. J., Obermeier, M., Schennach-Wolff, R., Bauer, M., Adli, M., Kronmüller, K., Nickel, T., Brieger, P., Laux, G., Bender, W., Heuser, I., Zeiler, J., Gaebel, W., & Seemüller, F. Response and remission criteria in major depression--a validation of current practice. Journal of psychiatric research, 2010, 44(15): 1063–1068.
Berman, M. G., Peltier, S., Nee, D. E., Kross, E., Deldin, P. J., & Jonides, J. Depression, rumination and the default network. Social cognitive and affective neuroscience, 2011, 6(5), 548–555.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
